MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.4500
+0.0600 (+4.32%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.3900
Open1.4100
Bid1.42 x 36900
Ask1.45 x 27000
Day's Range1.3900 - 1.4500
52 Week Range0.9400 - 3.3700
Volume1,670,251
Avg. Volume2,253,180
Market Cap270.083M
Beta (3Y Monthly)2.79
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • GuruFocus.com12 days ago

    Weekly CFO Buys Highlight

    Insiders pile on shares of Dynex Capital, MannKind and Martin Midstream Partners

  • GlobeNewswire13 days ago

    Market Trends Toward New Normal in MannKind, IDEX, Belden, Bright Horizons Family Solutions, Masonite International, and Veritiv — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 05, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Zacks Small Cap Research27 days ago

    MNKD: Update From Our Meeting With MNKD at JPM

    The International Diabetes Federation’s (IDF) Diabetes Atlas (8th edition) has estimated that approximately 30 million people were living with diabetes in 2017 in the U.S. According to the CDC, about 1.5 million new cases are diagnosed per year. Although insulin injection pens are ubiquitous and generally convenient to carry around, adherence to therapy has remained a challenge primarily due to hypo/hyperglycemia and, to some extent, as a result of anxiety associated with an injection, local sensitivity, pain and bruising. One of the biggest challenges for the company has been accelerating growth of Afrezza.

  • ACCESSWIRE27 days ago

    Biotech Stocks on the Move

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold ...

  • How to spot risky biotech companies and six to avoid now
    MarketWatchlast month

    How to spot risky biotech companies and six to avoid now

    With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.

  • GlobeNewswirelast month

    MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company’s inhaled insulin, Afrezza, for as little as $4 a day.

  • GlobeNewswire2 months ago

    MannKind Corporation to Hold Investor Conference Call

    WESTLAKE VILLAGE, Calif., Dec. 27, 2018 -- MannKind Corporation (NASDAQ: MNKD) will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM.

  • How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own?
    Simply Wall St.2 months ago

    How Many MannKind Corporation (NASDAQ:MNKD) Shares Do Institutions Own?

    A look at the shareholders of MannKind Corporation (NASDAQ:MNKD) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...

  • Why MannKind Stock Is Plunging Today
    Motley Fool2 months ago

    Why MannKind Stock Is Plunging Today

    Shares tumble after the biopharma raises capital from a dilutive common-stock offering.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and MannKind

    NEW YORK, NY / ACCESSWIRE / December 20, 2018 / U.S. equities closed down on Wednesday as the anticipated interest rate increase was confirmed by the Federal Reserve, following Chairman Jerome Powell’s ...

  • GlobeNewswire2 months ago

    MannKind Announces Pricing of $40 Million Public Offering

    MannKind Corporation (MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of its common stock.  Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $1.50, for a gross deal size of $40.0 million, not including any future proceeds from the exercise of the warrants and before deducting the underwriting discounts and commissions and offering expenses. The shares of common stock and warrants can only be purchased together but will be issued separately and will be immediately separable upon issuance.  The offering is expected to close on December 26, 2018, subject to customary closing conditions.

  • GlobeNewswire2 months ago

    MannKind Announces Commencement of Public Offering

    MannKind Corporation (MNKD) (MannKind) today announced that it has commenced an underwritten public offering to issue and sell shares of its common stock and warrants to purchase shares of its common stock. Leerink Partners is acting as sole book-running manager for the offering. The securities described above are being offered by MannKind pursuant to a shelf registration statement on Form S-3 (No. 333-210792) previously filed by MannKind with the Securities and Exchange Commission (SEC) on April 18, 2016 and declared effective on April 27, 2016.

  • Zacks Small Cap Research2 months ago

    MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target

    Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.

  • ACCESSWIRE2 months ago

    Biotech Stocks Beating the Market

    HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Here are several biotech plays to pay close attention to in the coming sessions. Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), MannKind ...

  • GlobeNewswire3 months ago

    MannKind Appoints Christine Mundkur to its Board of Directors

    MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November 27, 2018.  Ms. Mundkur will also serve as a member of the Audit Committee of the Board. Ms. Mundkur brings 25 years of experience in the pharmaceutical industry to the MannKind Board. “Christine brings a tremendous wealth of experience to our board of directors,” said Kent Kresa, Chairman of the Board of MannKind Corporation.

  • Analysts: Why United Therapeutics has had a streak of licensing deals
    American City Business Journals3 months ago

    Analysts: Why United Therapeutics has had a streak of licensing deals

    United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT

    Q3 2018 MannKind Corp Earnings Call

  • Associated Press4 months ago

    MannKind: 3Q Earnings Snapshot

    On a per-share basis, the Westlake Village, California-based company said it had a loss of 16 cents. The biopharmaceutical company posted revenue of $4.5 million in the period. The company's shares closed ...

  • United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript

    UTHR earnings call for the period ending September 30, 2018.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Altimmune and MannKind

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...

  • Why MannKind Corp. Soared 16.4% Tuesday
    Motley Fool4 months ago

    Why MannKind Corp. Soared 16.4% Tuesday

    The company has completed its planned transaction with United Therapeutics.

  • PR Newswire4 months ago

    United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

    RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.  MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.